KABLA acquires Laboratorios DAI en Mexico’s diagnostics devices portfolio.

 

Jul 05, 2018, 09:00 ET.

MONTERREY, Mexico, July 5th 2018 / The mexican company Kabla Comercial S.A. de C.V. (KABLA) has reached an agreement with LABORATORIOS DAI DE MÉXICO S.A. de C.V. to acquire their Diagnostics Division, which includes the transfer of distribution licenses, health permits, inventories, and operations. This deal is effective immediately, starting on July 1st 2018.

With this acquisition, KABLA will be nationally supplying diagnostics devices for in vitro use, adding to its extensive national network of market-leading brands like BOULE (Hematology), TECHNO-MEDICA (Gasometry), ELITECH (Blood Chemistry), INSTITUT VIRION SERION (Immunoassay), ERBA (Urinalysis), GOLDSITE (Nephelometry), among others, whose main purpose is to fulfill the needs of epidemiology, reference, and clinical analysis labs, as well as clinics that require equipment and reagents.

With the completion of this agreement, DAI plans to focus on prioritizing its Blood Bank devices portfolio with the purpose of reaffirming itself as the leader in that market segment. It’s worth mentioning that DAI is not only a leading company in Mexico, but also in Colombia and Venezuela, where they have 40 years experience in the market and it’s one of the biggest companies in latin america.

Meanwhile, with this new product line, Kabla is abiding by its firm commitment to maintain dynamic and sustainable growth, which will allow it to have a better market consolidation in the Health Care sector through a bigger and better selection of specialized, differentiated, high quality products. Furthermore, this acquisition will yield important operational, financial, and market benefits, which will be reflected by offering more competitive products for Clinical Analysis Laboratories in Mexico.

By:

Strategic Planning

Partido de Inicio
×